Source comparison
CJC-1295 vs Sermorelin: Research Application Comparison
Half-Life 8–12 minutes 6–8 days Sermorelin preserves natural pulsatile rhythm; CJC-1295 produces sustained elevation Injection Frequency Daily (typically pre-sleep) 1–2× weekly Sermorelin requires consistent adherence; CJC-1295 reduces administration burden GH
This comparison does not assign a generated winner or score.
- Half-Life
- 8–12 minutes
- 6–8 days
- Sermorelin preserves natural pulsatile rhythm; CJC-1295 produces sustained elevation
- Injection Frequency
- Daily (typically pre-sleep)
- 1–2× weekly
- Sermorelin requires consistent adherence; CJC-1295 reduces administration burden
- GH Secretion Pattern
- Pulsatile (mimics circadian rhythm)
- Sustained baseline elevation
- Sermorelin ideal for circadian studies; CJC-1295 better for cumulative IGF-1 accumulation
- IGF-1 Peak
- 2–4 hours post-injection
- 3–5 days post-injection
- Sermorelin produces transient spikes; CJC-1295 sustains elevation across days
- Receptor Downregulation Risk
- Low (brief occupancy)
- Moderate (prolonged occupancy)
- Daily pulsatile dosing with Sermorelin reduces desensitisation risk vs continuous CJC-1295 exposure
- Professional Assessment
- Sermorelin is the preferred choice for research requiring preservation of natural GH pulsatility and minimal disruption to circadian feedback. CJC-1295 with DAC is better suited for studies targeting sustained IGF-1 elevation or protocols where less frequent administration is operationally necessary.